The Uncorrected Proofs
IMPORTANT TO KNOW
After the authors have received the letter of acceptance and have paid the publication fee, the uncorrected version of their article appears instantly on our web site. It provides DOI and dates of acceptance and online posting.
This „early bird“ version of the article has been made available at this early stage in order to provide the fastest access to the article and is not intended to be the final version. The manuscript will undergo copyediting, typesetting and review of the resulting proof before it is published in its final form. To be noted that changes to the article should not be requested at this stage; for the proofreading the authors will be contacted by the Editor. This first version of the article will be replaced by the final version as soon as the latter becomes available and moved from „Uncorrected proofs“ to the „Papers in press“.
N. Kumar Jain, M. Tailang, N. Thangavel, H. A. Makeen, M. Albratty, A. Najmi, H. A. Alhazmi, K. Zoghebi, M. Alagusundaram, H. Kumar Jain and B. Chandrasekaran
A comprehensive overview of selective and novel fibroblast growth factor receptor
inhibitors as a potential anticancer modality
M. Baković, M. Bago, L. Benić, M. Krajinović, T. Silovski, N. Dedić Plavetić, L. Turković, M. Sertić and M. Ortner Hadžiabdić
Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
A. Dugonjić Okroša, T. Silovski, N. Dedić Plavetić, H. Silovski, A. Kovačić and I. Mucalo
Beliefs about medicines’ association with endocrine therapy adherence in early breast cancer survivors in Croatia
J. Kovačić, D. Amidžić Klarić, N. Turk and A. Mornar
Size exclusion chromatography as green support for forced degradation study of adalimumab